JP2021510710A5 - - Google Patents

Info

Publication number
JP2021510710A5
JP2021510710A5 JP2020539000A JP2020539000A JP2021510710A5 JP 2021510710 A5 JP2021510710 A5 JP 2021510710A5 JP 2020539000 A JP2020539000 A JP 2020539000A JP 2020539000 A JP2020539000 A JP 2020539000A JP 2021510710 A5 JP2021510710 A5 JP 2021510710A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
nos
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020539000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510710A (ja
JP7316284B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/071711 external-priority patent/WO2019137548A1/en
Publication of JP2021510710A publication Critical patent/JP2021510710A/ja
Publication of JP2021510710A5 publication Critical patent/JP2021510710A5/ja
Application granted granted Critical
Publication of JP7316284B2 publication Critical patent/JP7316284B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020539000A 2018-01-15 2019-01-15 Tigitに対する抗体及びその多様体 Active JP7316284B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018072607 2018-01-15
CNPCT/CN2018/072607 2018-01-15
PCT/CN2019/071711 WO2019137548A1 (en) 2018-01-15 2019-01-15 Antibodies and variants thereof against tigit

Publications (3)

Publication Number Publication Date
JP2021510710A JP2021510710A (ja) 2021-04-30
JP2021510710A5 true JP2021510710A5 (cg-RX-API-DMAC7.html) 2022-02-07
JP7316284B2 JP7316284B2 (ja) 2023-07-27

Family

ID=67219401

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020539000A Active JP7316284B2 (ja) 2018-01-15 2019-01-15 Tigitに対する抗体及びその多様体

Country Status (11)

Country Link
US (1) US11708410B2 (cg-RX-API-DMAC7.html)
EP (1) EP3740508A4 (cg-RX-API-DMAC7.html)
JP (1) JP7316284B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200109313A (cg-RX-API-DMAC7.html)
CN (1) CN111601826B (cg-RX-API-DMAC7.html)
AU (1) AU2019207296A1 (cg-RX-API-DMAC7.html)
CA (1) CA3088332A1 (cg-RX-API-DMAC7.html)
IL (1) IL275737A (cg-RX-API-DMAC7.html)
SG (1) SG11202005595YA (cg-RX-API-DMAC7.html)
TW (1) TW201932489A (cg-RX-API-DMAC7.html)
WO (1) WO2019137548A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3618863T (lt) 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
WO2020127377A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ose免疫治療公司 包含il-7變體之雙官能分子
EP4147053B1 (en) 2020-05-07 2026-01-28 Institut Curie Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
CN111995681B (zh) * 2020-05-09 2022-03-08 华博生物医药技术(上海)有限公司 抗tigit的抗体、其制备方法和应用
WO2021257124A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Tigit及cd112r阻斷
US20240002500A1 (en) * 2020-11-23 2024-01-04 Guangdong Fapon Biopharma Inc. Anti-TIGIT Antibody or Antigen-Binding Fragment Thereof
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
CN114539418A (zh) * 2020-11-26 2022-05-27 上海华奥泰生物药业股份有限公司 双特异性抗体及其用途
WO2022148781A1 (en) 2021-01-05 2022-07-14 Institut Curie Combination of mcoln activators and immune checkpoint inhibitors
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
MX2023011964A (es) 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
CA3217279A1 (en) 2021-05-04 2022-11-10 Olga Ignatovich Anti-tigit antibodies and methods of use thereof
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
CN115466327B (zh) * 2021-06-10 2025-07-08 北京天广实生物技术股份有限公司 结合tigit的抗体及其用途
CN118871463A (zh) 2021-07-28 2024-10-29 基因泰克公司 用于治疗癌症的方法和组合物
KR20240046905A (ko) * 2021-08-20 2024-04-11 아케소 바이오파마, 인크. 항-TIGIT 항체 및 TGF-βR을 포함하는 융합 단백질, 이의 약학 조성물, 및 용도
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023138639A1 (zh) * 2022-01-24 2023-07-27 原启生物科技(上海)有限责任公司 靶向tigit的抗原结合蛋白及其用途
JP2025523387A (ja) 2022-06-07 2025-07-23 ジェネンテック, インコーポレイテッド 抗pd-l1アンタゴニストおよび抗tigitアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
EP4565610A1 (en) 2022-08-02 2025-06-11 Ose Immunotherapeutics Multifunctional molecule directed against cd28
WO2024041639A1 (en) * 2022-08-26 2024-02-29 Nanjing Legend Biotech Co., Ltd. Antibodies targeting tigit and uses thereof
CN116444653B (zh) * 2023-03-09 2024-03-15 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一株阻断性非洲猪瘟病毒单克隆抗体杂交瘤细胞株的制备与应用
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
JP2026512425A (ja) 2023-03-30 2026-04-16 オーエスイー・イミュノセラピューティクス 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
CN121219319A (zh) * 2023-06-27 2025-12-26 正大天晴药业集团股份有限公司 抗tigit抗体及其应用
WO2025068461A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
WO2025068452A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
CN117343182B (zh) * 2023-10-11 2024-12-03 首都医科大学附属北京胸科医院 抗人tigit抗体或其功能性片段及其应用
WO2025132831A1 (en) 2023-12-19 2025-06-26 Universite D'aix-Marseille N-heteroaryl derivatives and uses thereof for treating cancer
CN118290586B (zh) * 2024-04-02 2025-11-04 郑州伊美诺生物技术有限公司 一种分泌kod dna聚合酶单克隆抗体的杂交瘤细胞、单克隆抗体及其应用
WO2025242836A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2025262250A1 (en) 2024-06-20 2025-12-26 Negio Therapeutics Guanfacine derivatives and their uses
WO2026068705A1 (en) 2024-09-26 2026-04-02 Ose Immunotherapeutics Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof
CN120647762B (zh) * 2025-06-16 2026-01-23 首都医科大学附属北京友谊医院 一种抗β1-AR-ECII抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103073644B (zh) * 2012-12-31 2014-03-12 中国科学技术大学 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用
MX2016017288A (es) * 2014-07-16 2017-06-27 Genentech Inc Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer.
CA2957722C (en) 2014-08-19 2022-05-31 Merck Sharp & Dohme Corp. Anti-tigit antibodies
US10717783B2 (en) * 2014-12-22 2020-07-21 Zeren Gao Bispecific tetravalent antibodies and methods of making and using thereof
AR103268A1 (es) * 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
TWI715587B (zh) * 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Tigit結合劑和彼之用途
EP3337517A4 (en) * 2015-08-20 2019-04-17 Abbvie Stemcentrx LLC ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE
SG10202007764TA (en) * 2015-09-25 2020-09-29 Genentech Inc Anti-tigit antibodies and methods of use
PT3356413T (pt) * 2015-10-01 2022-04-04 Potenza Therapeutics Inc Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas
EP3565839A4 (en) * 2017-01-05 2021-04-21 Gensun Biopharma Inc. CHECKPOINT REGULATOR ANTAGONISTS

Similar Documents

Publication Publication Date Title
JP7813721B2 (ja) Nectin-4に対する抗体及びその用途
JP7150880B2 (ja) 抗-b7-h3抗体およびその用途
JP7562528B2 (ja) 抗体及びその用途
CN115052895B (zh) 抗SIRPα抗体及其用途
US20170210818A1 (en) Constant region antibody fusion proteins and compositions thereof
JP2021524242A (ja) 抗−ror1抗体およびその用途
JP7649744B2 (ja) Btn3a結合タンパク質及びその使用
WO2018053709A1 (en) The novel monoclonal antibodies to programmed death 1 (pd-1)
JP2015519375A5 (cg-RX-API-DMAC7.html)
JP2019527553A5 (cg-RX-API-DMAC7.html)
IL261666B1 (en) Binding proteins and methods of use thereof
JP2020508655A5 (cg-RX-API-DMAC7.html)
CN111635458A (zh) 靶向Sirpα的抗体或其抗原结合片段及其制备和应用
JP2024001073A5 (cg-RX-API-DMAC7.html)
JP7821159B2 (ja) Bcmaと結合する単一可変ドメイン及び抗原結合分子
WO2022045247A1 (ja) 抗切断型変異calr-cd3二重特異性抗体及び医薬組成物
CN113993901A (zh) 四价双特异性抗体、其制备方法和用途
JP2024515560A5 (cg-RX-API-DMAC7.html)
JP2025541367A (ja) 多価および多重特異性サイトカインアンタゴニスト
CA3208368A1 (en) Vegfa-binding molecules
WO2021084104A1 (en) Tetravalent antibody molecules
JP7821161B2 (ja) Bcmaと結合する単一可変ドメイン及び抗原結合分子
US20250011431A1 (en) Anti-canine pd-l1 antibodies
WO2020039049A1 (en) Anti-sirpg compounds
CN120035609A (zh) Pd-1激动剂抗体